BC Extra | Nov 27, 2019
Company News

With shares rising on M&A chatter, Arrowhead points to pipeline moves in 2020

Buoyed by news of this week's takeout of Medicines Co., Arrowhead is riding a wave of investor enthusiasm for RNAi therapeutics that has quintupled the company’s share price this year, and has boosted its valuation...
BioCentury | Sep 21, 2018
Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
BC Innovations | Oct 1, 2015
Product R&D

Escaping the liver

Having addressed one of the two big problems of RNAi delivery - getting therapeutic levels of the molecules inside cells - Arrowhead Research Corp. now believes it has solved the second, with a modification to its technology...
BC Extra | Sep 12, 2015
Clinical News

Arrowhead chooses RNAi candidate for ccRCC

Arrowhead Research Corp. (NASDAQ:ARWR) gained $0.68 (12%) to $6.40 on Friday after it selected ARC-HIF2 as its first development candidate using the company's dynamic polyconjugate (DPC) platform for RNAi delivery to tissues outside the liver....
Items per page:
1 - 4 of 4